Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01749085 · ClinicalTrials.gov registry record · Phase 1
Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug Levels
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01749085 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 14 participants.
The verdict
NCT01749085, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The study aims to determine what effect a high fat meal will have on the drug exposure of PF-04449913. The study also aims to determine the effect of a strong enzyme (CYP3A4) inhibitor on drug exposure of PF-04449913.
Interventions
- DRUG PF-04449913, ketoconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01749085
The ClinicalTrials.gov registry entry for NCT01749085 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-04449913, ketoconazole is the first listed.
NCT01749085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01749085 about?
NCT01749085 is a clinical study titled "Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug Levels". The study aims to determine what effect a high fat meal will have on the drug exposure of PF-04449913. The study also aims to determine the effect of a strong enzyme (CYP3A4) inhibitor on drug exposure of PF-04449913.
What is the current status of trial NCT01749085?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2012-12. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01749085?
The interventions under investigation include: PF-04449913, ketoconazole (DRUG).
Who is sponsoring clinical trial NCT01749085?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.